Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., . . . Motzer, R. J. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open.
Citação norma ChicagoAlbiges, Laurence, et al. "Nivolumab Plus Ipilimumab Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: Extended 4-year Follow-up of the Phase III CheckMate 214 Trial." ESMO Open 2020.
ציטוט MLAAlbiges, Laurence, et al. "Nivolumab Plus Ipilimumab Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: Extended 4-year Follow-up of the Phase III CheckMate 214 Trial." ESMO Open 2020.